Related Experiment Videos

Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma

Nancy D Borson1, Martha Q Lacy, Peter J Wettstein

  • 1Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA. borson.nancy@mayo.edu

Blood
|November 28, 2002
PubMed

Insights

Multiple myeloma involves abnormal B cell development. Researchers found altered B cell-specific activator protein (Pax5) and premature Blimp-1 expression in myeloma patients, suggesting a cause for abnormal plasma cell differentiation.

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Research

Background:

  • Multiple myeloma (MM) is a plasma cell malignancy.
  • B-cell development is regulated by key transcription factors like Pax5 and Blimp-1.
  • Aberrant B-cell differentiation is implicated in MM pathogenesis.

Purpose of the Study:

  • To investigate the expression and role of Pax5 isoforms in multiple myeloma.
  • To analyze Blimp-1 expression in B cells from MM patients and healthy controls.
  • To understand the relationship between Pax5 and Blimp-1 in MM B-cell development.

Main Methods:

  • Differential mRNA expression analysis comparing MM and normal plasma cells.
  • Investigation of Pax5 isoform usage in B cells from MM patients and healthy subjects.
  • Semiquantitative analysis of B lymphocyte-induced maturation protein (Blimp-1) mRNA levels.

Main Results:

  • An unidentified Pax5 isoform was detected in MM cells.
  • MM patients exhibited multiple Pax5 isoforms with low full-length Pax5 expression in B cells.
  • Blimp-1 was expressed in B cells of all MM patients but not in healthy controls.

Conclusions:

  • Altered Pax5 expression, including novel isoforms, is characteristic of B cells in multiple myeloma.
  • Premature Blimp-1 expression in MM B cells correlates with aberrant Pax5.
  • This altered gene expression may drive premature differentiation of B cells into plasma cells in MM.

Related Concept Videos